Butyrate Regulating Inflammatory Responses in Chronic Obstructive Pulmonary Disease via the Gut-Lung Axis Authors: Qiang Liu, Qian Fu, Caiyuan Sun, Chanli Liu, Chan Xiong, Mei Chen Published: 2026 ABSTRACT AbstractChronic obstructive pulmonary disease (COPD) poses a major global health challenge, yet current pulmonary-directed therapies offer only symptomatic relief without modifying the underlying systemic inflammatory pathology. The gut–lung axis has emerged as a pivotal cross-organ regulatory circuit in COPD progression, and butyrate—a key microbial short-chain fatty acid derived from dietary fibre fermentation—mediates pleiotropic immunomodulatory effects that bridge intestinal homeostasis and pulmonary inflammation. This narrative review synthesises preclinical and limited clinical evidence to elucidate the regulatory functions of butyrate in COPD inflammation via the gut–lung axis, organising its core mechanisms into four major modules: strengthening intestinal mucosal barrier integrity, suppressing type 2 innate lymphoid cell overactivation, restoring the Th17/Treg homeostatic balance, and interrupting pathological endothelial–macrophage inflammatory crosstalk. Importantly, the therapeutic potential of butyrate is phenotype-restricted; its anti-inflammatory actions are primarily validated in the type 2 inflammatory COPD subtype, which affects only 20–40% of patients, whereas robust evidence for efficacy in the predominant neutrophilic phenotype remains scarce. Translational hurdles further impede clinical application, including poor oral bioavailability due to first-pass hepatic metabolism, insufficient human clinical verification, and the theoretical risk of excessive immunosuppression at elevated concentrations. Moreover, most mechanistic inferences are drawn from in vitro studies and cigarette smoke-induced animal models that incompletely recapitulate the heterogeneous pathophysiology of human COPD. This review critically appraises the current theoretical framework of butyrate-mediated gut–lung co-regulation, delineates the applicable patient subsets and core limitations of butyrate intervention, and highlights priority research directions encompassing phenotype-stratified clinical trials, optimised targeted delivery systems, and comparative analyses of multiple short-chain fatty acids. Although butyrate offers a promising theoretical foundation for developing novel gut–lung coordinated disease-modifying strategies, rigorous stratified clinical validation remains essential to ascertain its genuine therapeutic value in practice.Keywords: butyrate, COPD, Gut-lung axis, ILC2s, Th17/Treg balance Introduction Chronic obstructive pulmonary disease (COPD) is a heterogeneous lung disease characterized by chronic respiratory symptoms (dyspnea, cough, sputum production) caused by persistent and often progressive airflow obstruction due to abnormalities in the airways (bronchitis, bronchiolitis) and/or alveoli (emphysema).1 As a major global public health issue, COPD currently affects over 400 million people worldwide, ranking third among the global causes of death and imposing a heavy burden on individual health and social and economic development.2 Despite the implementation of global public health strategies for risk factor control and standardized clinical management guidelines, the incidence, prevalence, and disease burden of COPD continue to rise annually, driven by population aging, persistent exposure to cigarette smoke, ambient air pollution, biomass fuel combustion, and occupational dust exposure. The progressive nature of COPD leads to a sustained decline in patients’ exercise tolerance, respiratory function, and health-related quality of life, while recurrent acute exacerbations significantly increase the risk of respiratory failure, cardiovascular comorbidities, and mortality, placing enormous pressure on healthcare systems worldwide.3,4 Current pharmacological mainstays—bronchodilators and inhaled corticosteroids (ICS)—predominantly provide symptomatic relief and local airway immunosuppression, without modifying the systemic immuno-inflammatory networks that underpin disease progression. Moreover, the long-term use of ICS is associated with an increased incidence of community-acquired pneumonia, particularly in multimorbid patients, which complicates the risk-benefit profile of this therapy.5 These therapeutic constraints underscore the need for disease-modifying interventions that target the fundamental pathophysiological mechanisms extending beyond the pulmonary compartment. The gut-lung axis is a key cross-organ regulatory pathway linking the respiratory and digestive systems, enabling bidirectional crosstalk between the two organs via multiple mechanisms, including immune regulation,6 transport of microbial metabolites,7 and modulation of the neuroendocrine network.8 This evolutionarily conserved inter-organ communication system is not only essential for maintaining physiological homeostasis but also plays a pivotal role in the pathogenesis of various systemic and organ-specific diseases. Accumulating evidence has demonstrated that the gut and lungs share a common embryonic origin, possess similar mucosal immune structures, and are continuously exposed to external environmental stimuli, forming a functional and regulatory unity.9 This also echoes the traditional Chinese medicine theory that the lung and the large intestine are exteriorly and interiorly related.10 Although the gut–lung axis is also implicated in asthma and interstitial lung diseases,11,12 its pathophysiological relevance in COPD is distinguished by three converging factors. First, cigarette smoke directly impairs both pulmonary and intestinal mucosa, eliciting a systemic inflammatory response that is considerably more pronounced than in other respiratory conditions.13 Second, the heavy comorbidity burden inherent to COPD—encompassing cardiovascular disease, metabolic syndrome, and osteoporosis—amplifies the clinical impact of gut-derived inflammation.14 Third, the progressive, age-related nature of COPD, compounded by recurrent exacerbations and polypharmacy,15 renders the intestinal ecosystem particularly susceptible to sustained dysbiosis and barrier disruption. Clinical evidence directly substantiates these mechanistic links: observational studies have documented that COPD patients commonly exhibit intestinal dysmotility, increased permeability, gut microbiota imbalance, and mucosal inflammation, with the degree of dysfunction correlating with disease severity and reduced quality of life.16 Mechanistically, intestinal flora imbalance has been shown to disrupt barrier integrity and trigger systemic inflammatory responses that may accelerate COPD progression.17 Under physiological conditions, the gut-lung axis maintains immune tolerance, microbial homeostasis, and mucosal barrier integrity; however, under pathological stimuli, this axis becomes dysregulated, initiating a vicious cycle of systemic inflammation that remotely affects distant organs. Within this framework, pulmonary inflammation in COPD is increasingly viewed not as a lung-intrinsic process, but as a manifestation of systemic immune dysregulation with a gut-origin component. Among the myriad microbial metabolites that mediate gut–lung crosstalk, butyrate has garnered particular attention for its pleiotropic immunomodulatory and barrier-protective properties. Butyrate is one of the major short-chain fatty acids (SCFAs) produced by gut microbiota via the fermentation of dietary fiber.18 As a four-carbon saturated fatty acid, butyrate is primarily synthesized by commensal anaerobes such as Ruminococcaceae and Lachnospiraceae in the distal colon,19 serving as a critical molecular mediator between the gut microbiota and host physiology. It is a core metabolite that maintains the integrity of the intestinal mucosal barrier and systemic immune homeostasis.20 Under physiological conditions, butyrate serves as the primary energy source for colonic epithelial cells, providing more than 70% of their adenosine triphosphate (ATP) demand through mitochondrial β-oxidation, which is essential for sustaining intestinal epithelial proliferation, differentiation, and survival.21 Beyond its bioenergetic function, butyrate exerts multiple physiological functions, including potent anti-inflammatory effects, promotion of intestinal epithelial cell proliferation and repair, modulation of gut microbiota composition, regulation of oxidative stress responses, and inhibition of pathological cell proliferation.22,23 These diverse actions converge on multiple nodes of the gut–lung inflammatory network, rendering butyrate a candidate mediator of inter-organ crosstalk in COPD. Despite this mechanistic promise, direct human evidence for butyrate-based interventions in COPD remains conspicuously limited: no randomized controlled trial has yet tested oral butyrate supplementation. The current evidence base is restricted to observational studies, animal models, and in vitro experiments. Moreover, most human studies establishing the gut–lung axis in COPD are cross-sectional, demonstrating association rather than causation. Whether gut dysbiosis actively drives COPD progression or merely reflects smoking, physical inactivity, and polypharmacy remains unresolved. These confounders, together with the multifaceted determinants of COPD progression—including exacerbation frequency, genetic predisposition, and socioeconomic factors such as malnutrition and recurrent antibiotic use24—must be carefully considered in future integrative studies. Consequently, a substantial chasm persists between mechanistic plausibility and clinical verification. While the gut–lung axis, with butyrate as a key metabolic node, remains a biologically attractive adjunctive target, rigorous, phenotype-stratified studies are urgently needed to translate this theoretical promise into actionable therapeutic strategies. This imperative for phenotype stratification arises from the considerable heterogeneity inherent to COPD. The disease comprises two main inflammatory endotypes that differ profoundly in immune profile and therapeutic implications. The neutrophilic endotype, accounting for approximately 60–70% of patients, is characterized by elevated neutrophils, Th17 cells, and IL-17, and is typically associated with cigarette smoke exposure and bacterial colonization. In contrast, the type 2 endotype, observed in roughly 20–40% of patients, shows elevated eosinophils, ILC2s, and type 2 cytokines (IL-4, IL-5, IL-13), and correlates with greater airway hyperresponsiveness, mucus hypersecretion, and heightened exacerbation risk.25–27 This endotypic distinction matters because butyrate’s primary mechanisms—ILC2 suppression and Th17/Treg modulation—are preferentially aligned with type 2 and Th17-driven pathways. In contrast, evidence supporting butyrate efficacy in neutrophilic COPD is limited and derived almost exclusively from animal models. Evidence from cigarette smoke-induced mouse models supports the protective effects of butyrate-producing probiotics against systemic inflammation in COPD;28 However, these models typically exhibit a mixed or neutrophilic-dominant phenotype, which limits direct extrapolation of the findings to human type 2-predominant disease. Superimposed on this biological limitation is a pharmacokinetic one: oral butyrate is absorbed via monocarboxylate transporter 1 (MCT1)/sodium-coupled monocarboxylate transporter 1 (SMCT1) in the proximal gut and preferentially consumed through mitochondrial β-oxidation in colonocytes, a pathway with saturable flux. This efficient uptake-and-metabolism machinery, combined with first-pass hepatic extraction, severely restricts oral bioavailability. Consequently, millimolar colonic concentrations achieved physiologically are not replicable by simple oral supplementation, underscoring the need for optimized delivery strategies.29 Optimal dosing for butyrate in COPD remains undefined, and each administration route—oral, rectal, probiotic plus prebiotic combinations, or colonic-release formulations—carries distinct limitations. Furthermore, the other major SCFAs, acetate and propionate, exert complementary effects that may intersect with butyrate-mediated pathways. Acetate and propionate have been shown to suppress NETosis via GPR43 activation in COPD models,30 and these three SCFAs effectively rebalanced the Th17/Treg axis by suppressing Th17 differentiation while promoting Treg cell expansion.31 Clinically, plasma propionate concentrations were inversely associated with severely obstructive COPD and frequent exacerbations,32 and faecal acetate levels positively correlated with FEV1 in smokers with emphysema. In a smoking-induced murine model, acetate or propionate supplementation attenuated alveolar destruction and pulmonary inflammation, with propionate specifically reducing the Th17 cell population.33 However, the optimal ratios and the relative contributions of each SCFA to the overall therapeutic effect—particularly in the context of the gut–lung axis and COPD endotypes—remain unexplored, and no study has systematically compared different combinations or ratios of acetate, propionate, and butyrate in COPD models or patients. Collectively, these intertwined biological and pharmacological constraints should inform the design of future phenotype-stratified and delivery-optimized clinical studies. With these intertwined considerations—limited clinical evidence, endotypic heterogeneity, and pharmacokinetic barriers—in mind, this review systematically synthesizes recent advancements regarding the central immunomodulatory and barrier-protective roles of butyrate in COPD. We specifically delve into its multi-target synergistic mechanisms, which include: fortifying the intestinal barrier to block gut-derived systemic inflammation; modulating respiratory immune landscapes by suppressing ILC2s hyperactivation and restoring the Th17/Treg balance; and ameliorating pathological endothelial-macrophage crosstalk and pro-inflammatory signaling cascades. By comprehensively mapping these interactions within a phenotype-aware and translationally realistic framework, this review aims to provide a robust theoretical foundation for developing butyrate-based “gut-lung co-therapies”, while highlighting the critical gaps that must be addressed to move from bench to bedside. Butyrate Enhances Intestinal Barrier Function, Blocking Gut-Derived Inflammation The intestinal mucosa, a key site for nutrient absorption, also acts as a selective permeability barrier against invasion by exogenous pathogens and toxins; the integrity of its structure and function is critical for attenuating systemic inflammatory responses and reducing the risk of tissue damage.34 The intestinal barrier is a complex multi-layered structure composed of the intestinal microbiota, mucus layer, epithelial cells, tight junction complexes, and underlying immune cells, which synergistically prevent the uncontrolled entry of luminal contents into the systemic circulation. Disruption of this barrier leads to increased intestinal permeability, a pathological condition commonly referred to as “leaky gut”, which is a prerequisite for the activation of gut-derived systemic inflammation.35 Existing research confirms that patients with COPD commonly exhibit intestinal barrier impairment.16 Butyrate, as a central effector factor regulating intestinal barrier function, can strengthen the defensive capacity of the intestinal barrier through multiple complementary pathways,36 thereby blocking the occurrence and spread of gut-derived inflammation at its source. Ultimately, this contributes to alleviating pulmonary inflammatory damage in patients with COPD by interrupting the gut-lung inflammatory amplification loop. The uptake and metabolism of butyrate by colonic epithelial cells enhances intestinal epithelial barrier integrity by upregulating the expression of key tight junction protein genes, including claudin-1, claudin-7, zonula occludens-1 (ZO-1), zonula occludens-2 (ZO-2), and junctional adhesion molecule A (JAM-A).37 Tight junction complexes are the primary structural determinants of epithelial permeability, and their reduced expression or dysfunction is a hallmark of intestinal barrier damage. The underlying mechanism unfolds at two aspects. Firstly, butyrate directly induces the transcriptional activation of genes encoding tight junction structural components through histone acetylation modification, increasing the synthesis of tight junction proteins. Secondly, it modulates the activity of key transcription factors such as signal transducer and activator of transcription 3 (STAT3) and specificity protein 1 (SP1), thereby mediating the reorganization and functional optimization of tight junction proteins at the post-translational level. Ultimately, these actions work in concert to promote the repair and maintenance of the epithelial barrier function, reducing paracellular permeability.38 Additionally, butyrate serves as a preferred oxidative energy substrate for colonic cells. Its cellular uptake and metabolism effectively increase cellular oxygen consumption, maintaining the anaerobic microenvironment within the gut lumen, which is critical for the stability of commensal anaerobes and the suppression of pathogenic bacteria. This oxygen-consuming metabolism promotes the stable expression of hypoxia-inducible factor-1α (HIF-1α).39 Beyond this oxygen-dependent mechanism, butyrate can also directly inhibit prolyl hydroxylase (PHD), the enzyme that mediates HIF degradation under normoxic conditions, thereby blocking HIF ubiquitination and proteasomal degradation and further enhancing its stability.40 This PHD-inhibitory effect has been extended by a subsequent study from the same group demonstrating that 4-mercapto butyrate (MBA), a butyrate mimetic, stabilizes HIF more potently and lastingly than butyrate itself in intestinal epithelial cells through oxygen consumption, iron chelation, and PHD inhibition, independent of β-oxidation. In vivo, MBA induced systemic HIF stabilization and elevated serum erythropoietin more effectively than butyrate, suggesting that butyrate mimetics may overcome the rapid metabolism that limits native butyrate’s clinical utility.41 As a master transcription factor, HIF-1α has been confirmed to regulate the expression of mucins (MUC), antimicrobial peptides (AMP), and tight junction proteins, thereby strengthening intestinal mucosal barrier function.42 While HIF-1α stabilization reinforces intestinal barrier integrity, its sustained activation in the pulmonary vasculature has been established as a pathogenic driver of vascular remodeling and pulmonary hypertension—a common COPD comorbidity—by promoting pulmonary artery smooth muscle cells (PASMC) proliferation, migration, and fibrosis.43–45 Whether butyrate-mediated PHD inhibition could inadvertently exert similar effects in the lung remains unknown and awaits future investigation. Collectively, these findings indicate that butyrate and its mimetics reinforce intestinal barrier integrity through both oxygen-dependent and direct PHD-inhibitory mechanisms converging on HIF-1α-mediated transcriptional regulation, supporting the mechanistic basis for butyrate-based gut-lung co-therapy in COPD. Furthermore, butyrate promotes goblet cell differentiation, proliferation, and secretion of the major mucin protein MUC2, modulating the thickness and viscosity of the intestinal mucus layer, thereby further enhancing the defensive capacity of the intestinal mucosal barrier.46 The mucus layer acts as the first line of defense against luminal pathogens and toxins, preventing direct contact between microorganisms and epithelial cells. Through these multiple interconnected mechanisms—enhancing tight junction expression, stabilizing HIF-1α, promoting mucus secretion, and maintaining microbial homeostasis—butyrate collectively reinforces epithelial tight junctions and improves mucus barrier integrity, significantly enhancing intestinal barrier function and effectively blocking the cross-organ propagation of gut-derived inflammation to the lungs (Figure 1) (Created with BioGDP.com)47 These findings derive primarily from in vitro and animal studies. Whether butyrate exerts comparable barrier-strengthening effects in the human COPD gut at physiologically achievable concentrations remains to be directly tested. Mechanisms of butyrate in preserving intestinal mucosal barrier integrity via HIF-1α signaling. Butyrate exerts protective effects on the intestinal barrier through dual pathways. On the left, butyrate promotes the secretion of MUC2 from goblet cells to strengthen the mucus layer. On the right (magnified view), butyrate enters intestinal epithelial cells and is metabolized in the mitochondria, consuming oxygen (O2) and leading to intracellular hypoxia (Low O2). This local hypoxic state, alongside the direct inhibition of prolyl hydroxylase domain (PHD) enzymes by butyrate, stabilizes Hypoxia-Inducible Factor 1-alpha (HIF-1α). Stable HIF-1α translocates to the nucleus to upregulate the transcription of tight junction proteins, including ZO-1, Claudin, and JAM-A. (Note: solid arrows (→) indicate pathway progression; flat-headed lines (—|) indicate inhibition). Targeted Inhibition of Type 2 Innate Lymphoid Cells (ILC2s) Function Type 2 innate lymphoid cells (ILC2s), as a key functional subset of the innate immune system lacking rearranged antigen receptors,48 play an important role in the development and progression of allergic inflammation49 and chronic inflammation50 owing to their ability to rapidly respond to damage and inflammatory signals without prior sensitization. ILC2s are tissue-resident immune cells enriched in mucosal surfaces such as the lungs and intestines, serving as a critical bridge between innate and adaptive immunity. Dysregulation of ILC2s is closely linked to the pathological processes of various chronic inflammatory diseases, including allergic asthma, atopic dermatitis, and chronic obstructive pulmonary disease. Based on differences in activation characteristics and functional phenotypes, ILC2s can be further divided into inflammatory type 2 innate lymphoid cells (iILC2s) and natural type 2 innate lymphoid cells (nILC2s).51 These two subtypes differ significantly in developmental origin, tissue distribution, recruitment mechanisms, activation pathways, cytokine secretion profiles, and effector functions within the inflammatory microenvironment, providing a basis for their distinct roles in regulating different inflammatory contexts. nILC2s are constitutively present in mucosal tissues under physiological conditions, involved in tissue repair and immune homeostasis; in contrast, iILC2s are induced and expanded under inflammatory stimuli, exhibiting strong pro-inflammatory activity and tissue migration capacity.52 COPD is characterized by a highly heterogeneous inflammatory profile,53 with distinct immune cell infiltration patterns and cytokine signatures among different patient subgroups. Among these inflammatory phenotypes, neutrophilic inflammation represents the most prevalent clinical phenotype,54 associated with cigarette smoke exposure, bacterial infections, and severe airflow limitation. Nevertheless, accumulating clinical evidence indicates that approximately 20–40% of COPD patients exhibit a type 2 inflammatory signature, marked by elevated levels of type 2 cytokines such as IL-4, IL-5, and IL-13.25,26 Notably, compared to those with neutrophilic inflammation, patients displaying type 2 inflammatory COPD typically demonstrate more severe airway hyperresponsiveness, mucus hypersecretion, and airway remodeling, as well as a higher frequency of acute exacerbations and poorer clinical prognosis.55 Given their role as key initiators and amplifiers of type 2 immunity, ILC2s are thought to contribute critically to the pathogenesis and progression of this clinical subset,56 serving as a central regulatory node linking the gut-lung axis to type 2 inflammation in COPD. Existing studies have established that ILC2s exert a dual regulatory mechanism on Th2 cell differentiation during AECOPD: on one hand, ILC2s can directly present antigens to naive T cells via surface expression of major histocompatibility complex class II (MHC II) molecules and co-stimulatory molecules, initiating the directed differentiation of Th2 cells;57 on the other hand, ILC2s can activate the Notch-GATA-binding protein 3 (GATA3) signaling pathway—where binding of Notch receptors to ligands triggers downstream signal cascades, enhancing the expression and activation of GATA3, the key transcription factor for Th2 cells, thereby reinforcing Th2 cell differentiation and functional maintenance.58 Pathologically, excessive Th2 differentiation disrupts immune homeostasis, promotes aberrant humoral immune responses, eosinophilic infiltration, and mucus hypersecretion, ultimately contributing to accelerated airway inflammation and progressive lung function decline among COPD patients.59 This regulatory pathway indicates that ILC2s can precisely modulate the differentiation process of Th2 cells, serving as a central regulatory node in type 2 inflammation in COPD patients, directly influencing the intensity of inflammatory responses and disease prognosis. Moreover, studies have reported elevated levels of iILC2s in both the lung and intestinal mucosal tissues of patients with stable COPD and during acute exacerbations.60 This finding not only reinforces the central role of ILC2s in COPD pathophysiology but also implies the involvement of the gut–lung axis in cross-organ inflammatory regulation. As the body’s largest immune barrier, the intestinal mucosa can become impaired under the systemic inflammation associated with COPD, leading to local activation and subsequent entry of iILC2s into the systemic circulation. These cells are then recruited to the lungs via chemotactic signals from the pulmonary inflammatory microenvironment, such as C-C motif chemokine ligand 17(CCL17) and C-C motif chemokine ligand 22(CCL22), which are ligands for the C-C chemokine receptor 4(CCR4) highly expressed on iILC2s.61 Once recruited to the lungs, iILC2s contribute to inflammation amplification through two mechanisms: first, by secreting type 2 cytokines such as IL-5 and IL-13, directly exacerbating airway inflammation, eosinophil activation, and mucus hypersecretion; second, by synergizing with locally resident nILC2s, enhancing each other’s activation and cytokine output, thus forming an inflammatory amplification loop that ultimately intensifies type 2 inflammation and airway damage in the lungs.62 In summary, ILC2s play an irreplaceable central role in type 2 inflammation in COPD through subtype-specific regulation—particularly the gut-lung migration and functional activation of iILC2s—and its dual regulatory mechanism on Th2 cell differentiation. Related studies have found that butyrate, a metabolite derived from gut microbial fermentation of dietary fiber, can suppress ILC2s-dependent airway inflammation in the lungs.63 The underlying mechanism involves the specific inhibition of histone deacetylase (HDAC) activity by butyrate, which subsequently activates downstream epigenetic and transcriptional regulatory pathways. As a class I/II HDAC inhibitor, butyrate induces chromatin relaxation and histone acetylation, modulating the expression of key transcription factors governing ILC2s function. On one hand, it significantly enhances the transcription and expression of nuclear factor interleukin-3 regulated (NFIL3), a transcriptional repressor that inhibits ILC2s development and activation; on the other hand, it downregulates the expression of GATA3. GATA3 is a core transcription factor regulating ILC2s proliferation, activation, and functional maintenance;64 its suppressed expression directly blocks the aberrant expansion of ILC2s and simultaneously reduces the synthesis and secretion of type 2 cytokines including IL-4, IL-5, and IL-13.61 Since type 2 cytokines are central mediators of eosinophil infiltration, mucus hypersecretion, and airway hyperresponsiveness in COPD,65 their diminished secretion helps alleviate chronic inflammatory damage to the airway mucosa and ultimately mitigates airway inflammation. Importantly, this mechanistic pathway has been corroborated by several independent reviews, demonstrating that butyrate attenuates ILC2-driven airway inflammation via HDAC inhibition and GATA3 downregulation, with consequent reduction in type 2 cytokine production and airway hyperresponsiveness across in vitro and in vivo models.66 It is important to note, however, that these ILC2-regulatory effects have been primarily validated in preclinical settings; whether the same pathways are operational in human COPD remains an open question that warrants direct clinical investigation. In addition to directly regulating airway-resident ILC2s function, butyrate also modulates ILC2s phenotypic plasticity and tissue recruitment to further ameliorate pulmonary inflammation in COPD. Studies have shown that butyrate interferes with the conversion of colonic nILC2s into pro-inflammatory iILC2s, thereby reducing the generation and systemic dissemination of iILC2s, and also attenuates the recruitment of iILC2s from peripheral blood to the lungs by inhibiting the expression of chemokines such as CCL17 and CCL2260 (Figure 2) (Created with BioGDP.com)47 Together, these actions disrupt the progression of lung inflammation, offering a novel theoretical foundation and potential therapeutic avenues for targeted intervention in COPD, especially for patients with type 2 inflammatory phenotype. Butyrate suppresses ILC2 activation, effector functions, and lung recruitment via multiple pathways. Butyrate inhibits the inflammatory response driven by Group 2 innate lymphoid cells (ILC2s). Extracellularly, butyrate prevents the conversion of natural ILC2s (nILC2) into inflammatory ILC2s (iILC2) and decreases their recruitment to the lungs by inhibiting the expression of chemokines CCL17 and CCL22. Intracellularly, butyrate acts as a Histone Deacetylase (HDAC) inhibitor. The inhibition of HDAC leads to the upregulation of NFIL3, which subsequently blocks ILC2 development. Concurrently, HDAC inhibition downregulates GATA3, which directly suppresses ILC2 proliferation and the downstream production of type 2 cytokines (IL-4, IL-5, and IL-13). (Note: Solid arrows (→) indicate promotion, progression, or production; dashed arrows (–>) indicate cell recruitment; flat-headed lines (—|) indicate inhibition or blockade). Inhibition of Pro-Inflammatory Cell Activation and Inflammatory Mediator Release The persistent progression of lung inflammation in COPD is primarily driven by abnormal activation of pro-inflammatory cells and excessive release of inflammatory mediators.67 Pulmonary innate immune cells, including macrophages, neutrophils, and dendritic cells, act as the first responders to environmental insults and gut-derived inflammatory signals, playing a central role in the initiation and maintenance of COPD-related inflammation. These cells, which include macrophages, neutrophils, and dendritic cells, become activated in response to gut-derived toxins or environmental triggers such as cigarette smoke and air pollution, releasing large amounts of pro-inflammatory factors,68 including TNF-α, IL-1β, IL-6, chemokines, matrix metalloproteinases (MMPs), and reactive oxygen species (ROS). These inflammatory mediators further recruit circulating inflammatory cells into the lungs, amplify the inflammatory cascade, degrade extracellular matrix proteins, and aggravate damage to the airways and lung parenchyma, forming a self-sustaining inflammatory loop that drives disease progression. Butyrate, through regulation via the gut-lung axis, can inhibit the activation of pro-inflammatory cells in the lungs and reduce the release of inflammatory mediators, thereby alleviating the pulmonary inflammatory response in COPD. Acting as a signaling molecule, butyrate exerts its anti-inflammatory effects through both receptor-dependent and receptor-independent mechanisms, targeting multiple signaling pathways that govern pro-inflammatory cell function. Research has confirmed that butyrate can also regulate COPD inflammation through the G protein-coupled receptor 43 (GPR43)-mediated signaling pathway.69 As a key membrane receptor for SCFAs, GPR43 is widely expressed on immune cells (macrophages, neutrophils, T cells) and airway epithelial cells, serving as a critical sensor for microbial metabolites in the gut-lung axis. Its activation initiates downstream anti-inflammatory signaling cascades that counteract the pro-inflammatory pathways activated in COPD: on one hand, it specifically inhibits nuclear factor κB (NF-κB) signaling by blocking IκB phosphorylation and degradation, thereby preventing NF-κB nuclear translocation and the transcription of pro-inflammatory genes; on the other hand, it suppresses the assembly and activation of the NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome, a multi-protein complex that mediates the maturation and secretion of IL-1β and IL-18. Concurrently, butyrate blocks phosphorylation and nuclear translocation mediated by the c-Jun N-terminal kinase/p38 mitogen-activated protein kinase (JNK/p38 MAPK) pathway, another critical signaling axis driving inflammatory responses in COPD. This leads to a marked reduction in the synthesis and release of pro-inflammatory cytokines, including IL-1β, IL-6, and TNF-α, while also lowering the expression of MMP 9 and MMP 12 within the MMP family. Importantly, MMP 9 and MMP 12 contribute to airway remodeling and lung function decline in COPD by degrading the airway basement membrane, elastic fibers, and collagen matrix, leading to irreversible structural damage.70,71 Thus, via GPR43-mediated signaling, butyrate alleviates COPD pathology by curbing inflammatory cytokine release and limiting tissue remodeling damage, thereby further delineating its mechanistic role in COPD prevention and treatment. Most mechanistic evidence for GPR43-mediated butyrate effects derives from acute exposure models, and whether chronic supplementation maintains these effects without receptor desensitization or compensatory pathway activation remains unclear. Regulating Immune Balance and Cell Interactions Imbalance between helper T 17 cells (Th17 cells) and regulatory T cells (Treg cells) represents a core immune mechanism that drives persistent airway inflammation, lung tissue remodeling, and progressive decline in pulmonary function in COPD.72 The Th17/Treg axis is a critical determinant of immune homeostasis, governing the balance between pro-inflammatory and anti-inflammatory immune responses. Th17 cells secrete pro-inflammatory cytokines such as IL-17A and IL-22,73 recruiting inflammatory cells like neutrophils to infiltrate the airway mucosa, amplifying local inflammatory damage, promoting mucus secretion, and inducing tissue remodeling; while Treg cells, characterized by forkhead box P3 (FOXP3) expression, suppress excessive activation of effector immune cells through anti-inflammatory factors such as IL-10 and TGF-β, thereby maintaining immune homeostasis and preventing pathological inflammation.74 In COPD, the Th17/Treg balance is significantly skewed toward Th17 dominance, characterized by increased Th17 cells infiltration, elevated IL-17 levels, and reduced Treg cells frequency and function. This immune imbalance perpetuates chronic airway inflammation, impairs tissue repair mechanisms, and promotes the progression of airflow limitation.75 Butyrate can restore the balance of Th17/Treg cells ratios by directing the differentiation of naive CD4⁺ T cells in the gut-associated lymphoid tissue (GALT) and systemic immune system. Butyrate inhibits the polarization of naive CD4⁺ T cells into pathogenic Th17 cells by suppressing retinoic acid-related orphan receptor γt (RORγt), the master transcription factor of Th17 cells, and significantly promotes their differentiation into immunosuppressive Treg cells by enhancing FOXP3 expression,31 thereby alleviating chronic airway inflammation and lung tissue injury, ultimately ameliorating the core pathological features of COPD. This immune-modulatory effect of butyrate is transmitted from the gut to the lungs via the gut-lung axis, reshaping systemic immune homeostasis and attenuating pulmonary inflammation. However, a separate but equally important translational limitation concerns this Th17/Treg rebalancing effect: the effect has been primarily observed in animal models, and whether butyrate can durably remodel peripheral T cell homeostasis in COPD patients remains an open question that awaits direct clinical confirmation. Furthermore, butyrate, as one of the most prominent anti-inflammatory components within SCFAs, exerts lung protective effects by selectively modulating the crosstalk between vascular endothelial cells and macrophages, a critical cellular interaction in COPD pathogenesis. Cigarette smoke extract (CSE), a critical environmental trigger for the initiation and progression of COPD,53 specifically upregulates the expression and secretion of von Willebrand factor (VWF). As a major adhesion molecule primarily synthesized and released by vascular endothelial cells,76 aberrantly elevated VWF mediates abnormal adhesion and pathological signaling crosstalk between endothelial cells and macrophages, which in turn provokes pro-inflammatory activation of macrophages and functional damage to endothelial cells. This endothelial-macrophage crosstalk promotes vascular inflammation, increased vascular permeability, and inflammatory cell infiltration into the lung parenchyma, exacerbating COPD pathology. Building on this VWF-focused mechanism, accumulating evidence has verified that butyrate specifically inhibits CSE-induced VWF overexpression and disrupts the pathological crosstalk between endothelial cells and macrophages.77 This disruption operates through two complementary axes: on one hand, butyrate suppresses the secretion of pro-inflammatory cytokines—including IL-1β and TNF-α—from macrophages, thereby halting the initiation of the inflammatory cascade and reducing endothelial cell activation; on the other hand, it mitigates oxidative stress injury in endothelial cells, preserves the structural and functional integrity of the vascular barrier, and limits the transvascular infiltration of inflammatory mediators and cells into the lung parenchyma. Notably, a previous study reported that N-acetylcysteine alleviates COPD-associated pulmonary fibrosis in vitro and in vivo by inhibiting the VWF/p38 MAPK axis, regulating immune responses, and suppressing epithelial-mesenchymal transition (EMT).78 Whether similar mechanisms operate for butyrate is currently unknown, as direct evidence linking butyrate to VWF/p38 MAPK-mediated anti-fibrotic effects in COPD has not been established. Future studies are needed to clarify this possibility. Conclusion Overall, preclinical data summarized in this review strongly support butyrate as a promising and biologically plausible agent for gut-lung combined therapy in COPD. It exerts protective functions through four interrelated mechanistic pathways. These pathways strengthen intestinal tight junctions and preserve mucosal barrier integrity, suppress type 2 inflammation triggered by ILC2 cells, rebalance the disrupted Th17/Treg immune axis, and block the abnormal crosstalk between endothelial cells and macrophages. Collectively, these multi-target synergistic effects offer solid theoretical support for moving beyond traditional lung-only treatment strategies. It also makes systemic interorgan immune regulation a feasible and valuable direction for future COPD therapy. Despite these encouraging theoretical advantages, we cannot ignore several key uncertainties in current research evidence. To begin with, researchers have not yet defined a clear concentration threshold for butyrate. Its anti-inflammatory properties may shift to excessive immunosuppression beyond a certain dose, and this critical cutoff remains unconfirmed in existing COPD animal models. This issue is particularly important for advanced COPD patients. Such patients are highly vulnerable to recurrent infections, and excessive inhibition of immune activity may further weaken their ability to resist pathogens. This potential risk still lacks systematic pharmacological verification and safety assessment. Indeed, recent experimental evidence has provided a concrete warning. A recent study reported that sodium butyrate treatment in mice drastically suppressed follicular helper T cell differentiation, reducing the production of antigen-specific antibodies. When these mice were challenged with a viral pathogen, all butyrate-treated animals died, whereas the control group survived.79 This finding directly demonstrates that butyrate-induced immunosuppression can lead to aggravated infection and even mortality. Furthermore, butyrate has been shown to inhibit CD8+ T cell activation by suppressing IL-12 production from dendritic cells, further compromising antiviral immunity.80 For advanced COPD patients, who already face a high risk of recurrent respiratory infections, this immunosuppressive effect could be especially dangerous. Therefore, the safety margin of butyrate must be rigorously determined, and the potential for infection exacerbation should be a key consideration in any future therapeutic strategy. In addition, published studies show obvious publication bias. Most reported results are positive, while negative or neutral findings are rarely documented. This situation makes it difficult to objectively judge the true efficacy and stable performance of butyrate. Most notably, current mechanistic conclusions rely heavily on in vitro experiments and cigarette smoke-induced mouse models. The millimolar butyrate concentrations used in cell experiments are far higher than physiological levels in the human body. Meanwhile, mouse models cannot fully simulate the long-term aging state, multiple comorbidities and high infection risk of real human COPD. These defects greatly limit the clinical translation value of existing preclinical findings. Heterogeneity among COPD patients is another major obstacle to clinical transformation. The core therapeutic mechanisms of butyrate depend on ILC2 suppression and Th17/Treg regulation, which mainly target the type 2 inflammatory endotype. This specific endotype only appears in 20–40% of COPD patients. By contrast, most COPD patients present with a neutrophil-dominated inflammatory phenotype which dominates 60–70% of all clinical cases. There is still insufficient solid evidence to prove the efficacy of butyrate for this mainstream subtype, and the relevant data are almost all derived from animal models with limited reference value. Apart from these biological limitations, butyrate also faces prominent pharmacokinetic defects in practical application. Orally administered butyrate is quickly absorbed in the proximal intestine and metabolized by the liver during the first pass. Only a very small amount can reach the distal colon and enter systemic circulation. Routine oral supplementation therefore cannot achieve effective drug concentration at target sites. This means optimized delivery methods are urgently needed including colon-release preparations, rectal administration and synbiotic combination strategies. Future research needs to focus on several key directions to fill the above research gaps. First, it is necessary to carry out subgroup randomized controlled trials based on patient inflammatory phenotypes. Researchers can screen patients according to mature clinical biomarkers including blood eosinophil counts ≥300 cells/μL or elevated Th17 transcriptional levels. Combined with real-time pharmacokinetic monitoring, these trials can clarify which COPD subgroups can truly benefit from butyrate treatment. Second, short-chain fatty acids other than butyrate also deserve attention. We need to systematically explore the independent and combined effects of acetate and propionate, and clarify their optimal matching ratios with butyrate as well as their respective roles in maintaining gut-lung immune homeostasis. Third, developing new delivery systems is essential. New technologies that avoid proximal intestinal absorption and improve colonic bioavailability of butyrate can effectively solve its pharmacokinetic shortcomings. Meanwhile, we need to clarify a potential safety risk that has never been explored. It remains unclear whether butyrate-induced HIF-1α stabilization may worsen pulmonary vascular remodeling, and targeted mechanistic and safety studies are required to verify this concern. In short, butyrate has a complete and reliable mechanistic theoretical basis for the treatment of COPD, but supporting clinical evidence is still inadequate. There is a huge gap between its proven mechanistic advantages and verified clinical benefits. Only through rigorous translational research that fully considers patient endotype characteristics and optimizes drug delivery modes can we confirm the clinical value of butyrate. Further studies will determine whether this gut-derived microbial metabolite can be applied as an effective auxiliary treatment for specific COPD patients, or merely remain a theoretically feasible but clinically unapplicable research concept. Funding Statement The author(s) declare financial support was received for the research and/or publication of this article. This work was supported by the Project Program of Sichuan Science and Technology Program (No.2025ZNSFSC0629), and Chengdu University of Traditional Chinese Medicine University-Institutional Joint Innovation Fund (WXLH202402049). Abbreviations AMP, antimicrobial peptides; ATP, adenosine triphosphate; CCL17, C-C motif chemokine ligand 17; CCL22, C-C motif chemokine ligand 22; CCR4, COPD, chronic obstructive pulmonary disease; CSE, cigarette smoke extract; EMT, epithelial–mesenchymal transition; FOXP3, forkhead box P3; GALT, gut-associated lymphoid tissue; GATA3, GATA-binding protein 3; GPR43, G protein-coupled receptor 43; HDAC, histone deacetylase; HIF, hypoxia-inducible factor; HIF-1α, hypoxia-inducible factor-1α; iILC2s, inflammatory type 2 innate lymphoid cells; ILC2s, type 2 innate lymphoid cells; JAM-A, junctional adhesion molecule A; JNK/p38 MAPK, c-Jun N-terminal kinase/p38 mitogen-activated protein kinase; MBA, 4-mercapto butyrate; MHC II, major histocompatibility complex class II; MMPs, matrix metalloproteinases; MCT1, monocarboxylate transporter 1; MUC, mucins; nILC2s, natural type 2 innate lymphoid cells; NF-κB, nuclear factor κB; NFIL3, nuclear factor interleukin-3 regulated; NLRP3, NOD-like receptor family pyrin domain containing 3; PASMC, pulmonary artery smooth muscle cells; PHD, prolyl hydroxylase; RORγt, retinoic acid-related orphan receptor γt; ROS, reactive oxygen species; SCFAs, short-chain fatty acids; SMCT1, sodium-coupled monocarboxylate transporter 1; SP1, specificity protein 1; STAT3, signal transducer and activator of transcription 3; Th17 cells, T helper 17 cells; Treg cells, regulatory T cells; VWF, von Willebrand factor; ZO-1, zonula occludens-1; ZO-2, zonula occludens-2. Data Sharing Statement This is a review article based on published literature. All relevant references are listed in the reference section. No new, original, or unpublished datasets were generated or analyzed in this study. All figures are original illustrations created by the authors. Ethics approval and consent to participate This narrative review is based on published literature only. No new human participants, animals, or original data were involved in this study. Therefore, institutional review board (IRB) approval and informed consent were not applicable. Consent for Publication All figures in this article are original illustrations created by the authors. No identifiable personal data, images, or clinical materials from individual participants are involved. Therefore, consent for publication is not applicable. Author Contributions All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work. Disclosure The authors declare no competing interests. References Associated Data Data Availability Statement This is a review article based on published literature. All relevant references are listed in the reference section. No new, original, or unpublished datasets were generated or analyzed in this study. All figures are original illustrations created by the authors.